AB020. 183. Prevalence of sarcopenia and its impact on survival in breast cancer—a systematic review and meta-analysis

Simmons, Lydia; Cagney, David; Hassan, Farrah; Lim, John; O’Leary, Donal Peter; Liew, Aaron; Redmond, H. P.; Corrigan, Mark; O’Sullivan, M. J.; Kelly, Louise

doi:10.21037/map.2019.ab020

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, a gradual, generalized loss of skeletal muscle can be observed as the cancer progresses [ 41 ]. Partly in contrast to our present results, a systematic review of eight studies encompassing a total of 5744 patients with breast cancer found that sarcopenia also had a negative effect on overall survival in patients with non-metastatic cancer [ 5 ]. In our study, the low number of events in the non-metastatic group might have led to a lack of power for the detection of a statistically significant association between sarcopenia and mortality.…”

Section: Discussioncontrasting

confidence: 99%

“…The prevalence of sarcopenia in patients with cancer varies significantly according to the type of cancer and stage, the criterion or criteria applied, and the assessment methods used [ 4 ]. In a recent systematic review and meta-analysis of eight studies encompassing a total of 5744 patients with breast cancer, the prevalence of sarcopenia was 37.6% overall, 36.3% among patients with non-metastatic cancer, and 55.1% among those with metastatic cancer [ 5 ]. In another systematic review of older patients with cancer receiving radiotherapy, the prevalence of sarcopenia ranged from 42.8% to 72% [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort Study

et al. 2023

View full text Add to dashboard Cite

Older cancer patients have an elevated risk of sarcopenia. The aim was to estimate the prevalence of four criteria for sarcopenia case finding, assessment, diagnosis, and severity determination: abnormal strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F), low hand-grip strength (HGS), low arm circumference (AC, a muscle mass proxy), and low physical performance (PP). Sarcopenia (low HGS and AC) and severe sarcopenia (low HGS, AC, and PP) and their predictive values for 6-month mortality were estimated in the whole population and by metastatic status. We analyzed data from the NutriAgeCancer French nationwide study of cancer patients aged ≥70 referred for geriatric assessment before anti-cancer treatment. We performed Cox proportional hazards analysis for each criterion separately and all criteria combined. Overall, 781 patients from 41 geriatric oncology clinics were included (mean age: 83.1; females: 53%; main cancer types: digestive (29%) and breast (17%); metastases: 42%). The prevalence of abnormal SARC-F, low HGS, a low AC, low PP, sarcopenia, and severe sarcopenia were, respectively, 35.5%, 44.6%, 44.7%, 35.2%, 24.5%, and 11.7%. An abnormal SARC-F and/or low HGS, sarcopenia, and severe sarcopenia were associated with 6-month mortality in patients with metastases (adjusted hazard ratios [95% confidence interval]: 2.72 [1.34–5.49], 3.16 [1.48–6.75] and 6.41 [2.5–16.5], respectively). Sarcopenia was strongly predictive of 6-month mortality in patients with metastatic cancer.

show abstract

Section: Discussioncontrasting

confidence: 99%